Cameron Osterman

Cameron Osterman

Auto-generated profile, based on publicly available information

Cameron Osterman

Department of Molecular and Human Genetics, Baylor College of Medicine (BCM)

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
BVBhupesh Vaidya
Bhupesh Vaidya
YLYan Li
Yan Li
YKYoungDoo Kim
YoungDoo Kim
COCameron Osterman
Cameron Osterman
JRJean-Pierre Revelli
Jean-Pierre Revelli
HZHuda Y. Zoghbi
Huda Y. Zoghbi
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a prolonged prodromal stage that culminates in motor deficits. Current PD therapies primarily alleviate symptoms, underscoring the need for disease-modifying strategies. Glucagon-like peptide-1 (GLP-1) analogs showed early promise as candidate disease modifiers, but recent clinical results have been inconsistent, and their mechanism of action remains poorly defined. Here, we employed our Snca G51D/G51D knock-in mouse model to investigate the effects of subcutaneously administered GLP-1 analogs, semaglutide and lixisenatide. Both analogs reversed motor and non-motor deficits and reduced gliosis and detergent-insoluble α-synuclein. Bulk and single-nuclei transcriptomics together with CellChat-based intercellular communication analysis revealed that GLP-1 analogs normalize early striatal mitochondrial and inflammatory dysregulation and restore neuregulin (NRG) and neurexin (NRXN) signaling networks to wild-type levels. Treatment was effective when initiated either before or shortly after symptom onset, defining an early therapeutic window for GLP-1 analog therapy in PD.